Streetbeat News

MLTX

MoonLake Immunotherapeutics

https://www.moonlaketx.com

Industry

Biotechnology

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Open

51.98

Mkt cap

3.1B

Volume

401K

High

51.98

P/E Ratio

-38.45

52-wk high

64.98

Low

48.30

Div yield

N/A

52-wk low

37.55

Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on MoonLake (NASDAQ:MLTX) and maintained a price target of $86.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 12:55 pm

Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on MoonLake (NASDAQ:MLTX) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:07 pm

Several stocks experienced significant price movements in Tuesday's mid-day session. Tenon Medical withdrew its proposed public offering, causing its shares to climb 63.5%. Avalo Therapeutics agreed to divest AVTX-800 series, leading to a 52.6% gain. Cognyte Software reported better-than-expected Q2 results and issued FY24 guidance above estimates, resulting in a 24.8% gain. Xos was awarded a contract by the State of California, causing a 23% gain. The Beauty Health Company announced a business transformation program and a $100 million share repurchase, leading to a 16.6% jump. On the other hand, Acelyrin shares fell 60.8% after announcing disappointing trial results. CS Disco shares fell 22.1% after the company announced its CEO's departure.

Portfolio Pulse from Lisa Levin

September 12, 2023 | 5:44 pm

Barclays analyst Leon Wang maintains an Equal-Weight rating on MoonLake (NASDAQ:MLTX) and raises the price target from $41 to $59.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 4:15 pm

Several stocks recorded gains in Tuesday's trading session. Shengfeng Development Limited (SFWL), Cognyte Software Ltd. (CGNT), The Beauty Health Company (SKIN), Bitfarms Ltd. (BITF), MoonLake Immunotherapeutics (MLTX), TeraWulf Inc. (WULF), NextNav Inc. (NN), ImmunityBio, Inc. (IBRX), Casey's General Stores, Inc. (CASY), United Homes Group, Inc. (UHG), CleanSpark, Inc. (CLSK), Riot Platforms, Inc. (RIOT), IonQ, Inc. (IONQ), Cipher Mining Inc. (CIFR), GameStop Corp. (GME), Matrix Service Company (MTRX), Coinbase Global, Inc. (COIN), VinFast Auto Ltd. (VFS), Hut 8 Mining Corp. (HUT), and IAMGOLD Corporation (IAG) all saw increases in their share prices.

Portfolio Pulse from Lisa Levin

September 12, 2023 | 2:24 pm

During Tuesday's pre-market session, several health care stocks experienced significant movements. Tenon Medical, Cosmos Health, Avalo Therapeutics, Lyra Therapeutics, MoonLake, and T2 Biosystems saw increases in their share prices, while Sight Sciences, Orthofix Medical, Axcella Health, NovaBay Pharmaceuticals, EUDA Health Holdings, and Elutia experienced decreases.

Portfolio Pulse from Benzinga Insights

September 12, 2023 | 1:06 pm

Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on MoonLake (NASDAQ:MLTX) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 1:03 pm

MoonLake's shares are trading higher following the failure of rival Acelyrin's Phase 2b/3 trial of izokibep for Hidradenitis Suppurativa. MoonLake is also developing a treatment for the same condition.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:45 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on MoonLake (NASDAQ:MLTX) and maintained a $75 price target.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 10:20 am

Needham analyst Serge Belanger has reiterated a 'Buy' rating on MoonLake (NASDAQ:MLTX) and maintained a price target of $76.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 10:11 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.